title: RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling.
abstract: In the AD brain, there are elevated amounts of soluble and insoluble Abeta peptides which enhance the expression of membrane bound and soluble receptor for advanced glycation end products (RAGE). The binding of soluble Abeta to soluble RAGE inhibits further aggregation of Abeta peptides, while membrane bound RAGE-Abeta interactions elicit activation of the NF-kappaB transcription factor promoting sustained chronic neuroinflammation. Atomic force microscopy observations demonstrated that the N-terminal domain of RAGE, by interacting with Abeta, is a powerful inhibitor of Abeta polymerization even at prolonged periods of incubation. Hence, the potential RAGE-Abeta structural interactions were further explored utilizing a series of computational chemistry algorithms. Our modeling suggests that a soluble dimeric RAGE assembly creates a positively charged well into which the negative charges of the N-terminal domain of dimeric Abeta dock.
authors.affiliation: Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
authors.forename: Michael O
authors.initials: MO
authors.lastname: Chaney
authors.forename: W Blaine
authors.initials: WB
authors.lastname: Stine
authors.forename: Tyler A
authors.initials: TA
authors.lastname: Kokjohn
authors.forename: Yu-Min
authors.initials: YM
authors.lastname: Kuo
authors.forename: Chera
authors.initials: C
authors.lastname: Esh
authors.forename: Afroza
authors.initials: A
authors.lastname: Rahman
authors.forename: Dean C
authors.initials: DC
authors.lastname: Luehrs
authors.forename: Ann Marie
authors.initials: AM
authors.lastname: Schmidt
authors.forename: David
authors.initials: D
authors.lastname: Stern
authors.forename: Shi Du
authors.initials: SD
authors.lastname: Yan
authors.forename: Alex E
authors.initials: AE
authors.lastname: Roher
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism / Q000473:pathology; D000595:Amino Acid Sequence; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000378:metabolism; D019281:Dimerization; D004220:Disulfides / Q000737:chemistry; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D018625:Microscopy, Atomic Force; D008958:Models, Molecular; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000235:genetics / Q000378:metabolism*; D012995:Solubility
chemical_list: D016229:Amyloid beta-Peptides; D004220:Disulfides; D017127:Glycation End Products, Advanced; D007074:Immunoglobulin G; D010446:Peptide Fragments; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; C075222:amyloid beta-protein (1-42)